Skip to main content

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Clinical Sarcoma Research will cease to be published by BMC as of 31 December 2020. BMC will continue to host an archive of all articles previously published in the journal and all articles published in Clinical Sarcoma Research during its time with BMC will remain fully searchable via the BMC website.


  1. Authors: Zachary Burningham, Mia Hashibe, Logan Spector and Joshua D Schiffman

    Content type: Review

Aims and scope

Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.

Thematic series: The challenges of sarcoma

This thematic series explores the challenges clinicians face in early recognition and diagnosis of sarcomas. We're delighted to produce the series comprising of two review articles written by leading global experts in the field, in collaboration with Springer Healthcare IME.


The journal is an integral part of the euroSARC project funded by the European Commission through the 7th Framework Programme under Grant Agreement no. 278742.

Meet the Editors-in-Chief

Dr. Paolo G. Casali is head of the Adult Mesenchymal Tumour Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy. He serves as Secretary of the Ethics Committee of his institution. His research focuses on rare tumors, especially adult sarcomas, including gastrointestinal stromal tumors (GIST), and uncommon histological types. He is the Secretary of the Italian Sarcoma Group, and is a member of the EORTC Soft Tissue & Bone Sarcoma Group. He chairs the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which endeavours to exploit distant patient sharing in order to improve quality of care and diminish health migration for rare solid cancers. He acts as an Editor of START, an Italian-based, European state-of-the-art instrument on cancer treatment. He is a member of the Executive Board of ESMO as chair of the Public Policy/European Affairs Committee, and is Faculty Coordinator for Sarcoma. He is a member of the Policy Committee of ECCO. He teaches Medical Therapy of Rare Cancers at the Milan University postgraduate school in Oncology. 

Dr. Angelo Paolo Dei Tos is the Director of the Department of Oncology and Director of Anatomic Pathology at the General Hospital in Treviso, Italy, and Contract Professor of Pathology at the University of Padua School of Medicine. He is the Chairman of the Pathology Subcommittee of the Soft Tissue and Bone Group of EORTC, Founder and Past Chairman of the Working Group on Soft Tissue Tumor Pathology of the European Society of Pathology, Past President of the International Society of Bone and Soft Tissue Pathology, panel member for the WHO classification of Bone and Soft Tissue Sarcomas, member of the Board of Directors of the Connective Tissue Oncologic Society, and a faculty member of ESMO. He has authored or co-authored more than 140 peer reviewed scientific papers.

Annual Journal Metrics

  • Speed
    71 days to first decision for reviewed manuscripts only
    69 days to first decision for all manuscripts
    144 days from submission to first decision
    15 days from acceptance to publication

    93 Altmetric Mentions